TY - JOUR
T1 - Lung Transplantation in Older Patients With Cystic Fibrosis
T2 - Analysis of UNOS Data
AU - Weiss, Eric S.
AU - Allen, Jeremiah G.
AU - Modi, Monica N.
AU - Merlo, Christian A.
AU - Conte, John
AU - Shah, Ashish S.
N1 - Funding Information:
Supported in part by the Health Resources and Services Administration (234-2005-370011C) and the National Institutes of Health (NIH 2T32DK007713-12 ESW). The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.
PY - 2009/2
Y1 - 2009/2
N2 - Background: The lifespan for patients with cystic fibrosis (CF) is increasing. As a result, greater numbers of older CF patients are presenting for lung transplantation (LTx). The UNOS database provides an opportunity to examine outcomes for this population. Methods: We retrospectively reviewed UNOS data to identify 1,637 first-time LTx recipients with the indication of CF between 1999 and 2007. Patients were stratified by quartile age. Our primary end-point was all-cause mortality. Post-transplant survival was compared using Cox proportional hazards regression. Results: Of the patients who met the inclusion criteria, the distribution by age quartile was as follows: Quartile 1 (Q1), age 7 to 20 years, N = 408; Q2, 21 to 27, N = 470; Q3, 28 to 34, N = 365; and Q4, ≥35, N = 394. Patients in the lowest quartile had the lowest 5-year cumulative survival (43%); 19% lower than for patients in Quartile 4 (age ≥35, cumulative survival = 62%; p < 0.001). On multivariable analysis, patients in Q3 and Q4 had a 38% and 32% reduction in cumulative hazard for death, respectively (reference Q1, age 7 to 20) (hazards ratios: Q3, 0.62 [0.46 to 0.85], p < 0.001; Q4, 0.68 [0.5 to 0.93], p = 0.02). Thirty-day and 1-year cumulative survival were not different among the four quartiles (30-day survival: Q1, 96.4%; Q2, 96.2%; Q3, 96.2%; and Q4, 95.5% [p = 0.94]; 1-year survival: Q1, 83.7%; Q2, 83.1%; Q3, 85.4%; and Q4, 83.4% [p 0.88]). Increasing age was associated with decreases in early post-operative infections, reduction in the cumulative hazard of developing bronchiolitis obliterans (BO) syndrome, and decreases in hospitalizations and treatment for rejection. Conclusions: The UNOS database has provided a large series examining survival after LTx in older CF patients. LTx is safe in this group and older age may be protective against infection, rejection and BO syndrome.
AB - Background: The lifespan for patients with cystic fibrosis (CF) is increasing. As a result, greater numbers of older CF patients are presenting for lung transplantation (LTx). The UNOS database provides an opportunity to examine outcomes for this population. Methods: We retrospectively reviewed UNOS data to identify 1,637 first-time LTx recipients with the indication of CF between 1999 and 2007. Patients were stratified by quartile age. Our primary end-point was all-cause mortality. Post-transplant survival was compared using Cox proportional hazards regression. Results: Of the patients who met the inclusion criteria, the distribution by age quartile was as follows: Quartile 1 (Q1), age 7 to 20 years, N = 408; Q2, 21 to 27, N = 470; Q3, 28 to 34, N = 365; and Q4, ≥35, N = 394. Patients in the lowest quartile had the lowest 5-year cumulative survival (43%); 19% lower than for patients in Quartile 4 (age ≥35, cumulative survival = 62%; p < 0.001). On multivariable analysis, patients in Q3 and Q4 had a 38% and 32% reduction in cumulative hazard for death, respectively (reference Q1, age 7 to 20) (hazards ratios: Q3, 0.62 [0.46 to 0.85], p < 0.001; Q4, 0.68 [0.5 to 0.93], p = 0.02). Thirty-day and 1-year cumulative survival were not different among the four quartiles (30-day survival: Q1, 96.4%; Q2, 96.2%; Q3, 96.2%; and Q4, 95.5% [p = 0.94]; 1-year survival: Q1, 83.7%; Q2, 83.1%; Q3, 85.4%; and Q4, 83.4% [p 0.88]). Increasing age was associated with decreases in early post-operative infections, reduction in the cumulative hazard of developing bronchiolitis obliterans (BO) syndrome, and decreases in hospitalizations and treatment for rejection. Conclusions: The UNOS database has provided a large series examining survival after LTx in older CF patients. LTx is safe in this group and older age may be protective against infection, rejection and BO syndrome.
UR - http://www.scopus.com/inward/record.url?scp=59349107343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59349107343&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2008.11.903
DO - 10.1016/j.healun.2008.11.903
M3 - Article
C2 - 19201338
AN - SCOPUS:59349107343
SN - 1053-2498
VL - 28
SP - 135
EP - 140
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 2
ER -